Eclipse Study



Inclusion Criteria

- (1) Histologically-proven metastatic adenocarcinoma
- (2) Have failed at least one prior chemotherapy
- Primary Cohort, at least one of the prior treatment regimens must be a gemcitabine-based
- 2nd-line Cohort are not required to have a prior gemcitabine-based

Exclusion Criteria

- (1) Artificial joint(s) or other exogenous implant(s)
- (2) Cirhosis or ascites
- (3) Rapidly progressive disease
- (4) PE or DVT within 2 months
- (5) Pleural effusion
- (6) Immunodeficiency
- (7) HIV, hep B or C
- (8) Autoimmune disease
- (9) Systemic steroids
- (10)Prior GVAX or CRS-207